Literature DB >> 25986313

Expression profiles of human CCN genes in patients with osteoarthritis or rheumatoid arthritis.

Masatoshi Komatsu1, Yukio Nakamura, Masaaki Maruyama, Kazutoshi Abe, Ramida Watanapokasin, Hiroyuki Kato.   

Abstract

OBJECTIVE: Osteoarthritis (OA) and rheumatoid arthritis (RA) are widespread disabling joint disorders that are considered to be polygenic in nature. This study investigated the spatial expression patterns of all six known human CCN genes using end-stage OA and RA joint samples.
DESIGN: We performed in situ hybridization and histological analysis to investigate the spatial expression patterns of human CCN genes using joint tissues obtained during total knee and hip joint replacement procedures on patients with advanced OA or RA. Normal joint tissues taken while performing bipolar hip replacement surgeries were used as controls.
RESULTS: All CCN genes were expressed at higher levels in OA and RA synovial samples as compared with normal controls. Whereas CCN3 and CCN6 were undetectable in control, OA, and RA cartilage, CCN1, CCN2, CCN4, and CCN5 were expressed to a greater extent in OA and RA knee cartilage.
CONCLUSIONS: Our results indicate an involvement of several CCN genes in the pathophysiology of OA and RA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986313     DOI: 10.1007/s00776-015-0727-3

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  12 in total

1.  CCN1/CYR61-mediated meticulous patrolling by Ly6Clow monocytes fuels vascular inflammation.

Authors:  Beat A Imhof; Stephane Jemelin; Romain Ballet; Christian Vesin; Marc Schapira; Melis Karaca; Yalin Emre
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

Review 2.  Caught between a "Rho" and a hard place: are CCN1/CYR61 and CCN2/CTGF the arbiters of microvascular stiffness?

Authors:  Brahim Chaqour
Journal:  J Cell Commun Signal       Date:  2019-08-02       Impact factor: 5.782

Review 3.  Targeting CCN Proteins in Rheumatoid Arthritis and Osteoarthritis.

Authors:  Iona J MacDonald; Chien-Chung Huang; Shan-Chi Liu; Yen-You Lin; Chih-Hsin Tang
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 4.  Osteoarthritis: Novel Molecular Mechanisms Increase Our Understanding of the Disease Pathology.

Authors:  Susanne Grässel; Frank Zaucke; Henning Madry
Journal:  J Clin Med       Date:  2021-04-30       Impact factor: 4.241

Review 5.  Eyeing the Cyr61/CTGF/NOV (CCN) group of genes in development and diseases: highlights of their structural likenesses and functional dissimilarities.

Authors:  Izabela Krupska; Elspeth A Bruford; Brahim Chaqour
Journal:  Hum Genomics       Date:  2015-09-23       Impact factor: 4.639

6.  Picking a bone with WISP1 (CCN4): new strategies against degenerative joint disease.

Authors:  Kenneth Maiese
Journal:  J Transl Sci       Date:  2016-01-26

7.  Higher Serum CCN3 Is Associated with Disease Activity and Inflammatory Markers in Rheumatoid Arthritis.

Authors:  Yingying Wei; Linan Peng; Yi Li; Na Zhang; Ke Shang; Lihua Duan; Jixin Zhong; Jie Chen
Journal:  J Immunol Res       Date:  2020-05-09       Impact factor: 4.818

8.  NOV/CCN3 induces cartilage protection by inhibiting PI3K/AKT/mTOR pathway.

Authors:  Xiaojian Huang; Bowei Ni; Zekai Mao; Yang Xi; Xiangyu Chu; Rui Zhang; Xiaohu Ma; Hongbo You
Journal:  J Cell Mol Med       Date:  2019-08-27       Impact factor: 5.310

9.  Association of serum Cyr61 levels with peripheral arterial disease in subjects with type 2 diabetes.

Authors:  Bin Feng; Guidong Xu; Kangyun Sun; Kaipeng Duan; Bimin Shi; Nannan Zhang
Journal:  Cardiovasc Diabetol       Date:  2020-11-22       Impact factor: 9.951

Review 10.  Onset and Progression of Human Osteoarthritis-Can Growth Factors, Inflammatory Cytokines, or Differential miRNA Expression Concomitantly Induce Proliferation, ECM Degradation, and Inflammation in Articular Cartilage?

Authors:  Karen A Boehme; Bernd Rolauffs
Journal:  Int J Mol Sci       Date:  2018-08-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.